Nanotechnology used for Retinoblastoma: Comparison
Please note this is a comparison between Version 2 by Conner Chen and Version 1 by Sadanand Pandey.

Retinoblastoma is a rare type of cancer, and its treatment, as well as diagnosis, is challenging, owing to mutations in the tumor-suppressor genes and lack of targeted, efficient, cost-effective therapy, exhibiting a significant need for novel approaches to address these concerns. For this purpose, nanotechnology has revolutionized the field of medicine with versatile potential capabilities for both the diagnosis, as well as the treatment, of retinoblastoma via the targeted and controlled delivery of anticancer drugs via binding to the overexpressed retinoblastoma gene. Nanotechnology has also generated massive advancements in the treatment of retinoblastoma based on the use of surface-tailored multi-functionalized nanocarriers; overexpressed receptor-based nanocarriers ligands (folate, galactose, and hyaluronic acid); lipid-based nanocarriers; and metallic nanocarriers. These nanocarriers seem to benchmark in mitigating a plethora of malignant retinoblastoma via targeted delivery at a specified site, resulting in programmed apoptosis in cancer cells. The effectiveness of these nanoplatforms in diagnosing and treating intraocular cancers such as retinoblastoma has not been properly discussed, despite the increasing significance of nanomedicine in cancer management.

Retinoblastoma is a rare type of cancer, and its treatment, as well as diagnosis, is challenging, owing to mutations in the tumor-suppressor genes and lack of targeted, efficient, cost-effective therapy, exhibiting a significant need for novel approaches to address these concerns. For this purpose, nanotechnology has revolutionized the field of medicine with versatile potential capabilities for both the diagnosis, as well as the treatment, of retinoblastoma via the targeted and controlled delivery of anticancer drugs via binding to the overexpressed retinoblastoma gene. Nanotechnology has also generated massive advancements in the treatment of retinoblastoma based on the use of surface-tailored multi-functionalized nanocarriers.

  • Retinoblastoma
  • Cancer
  • Surface-tailored multi-functionalized nanoparticles
  • Metallic nanoparticle
  • Tumor-suppressor gene mutation
  • Nanotechnology
Please wait, diff process is still running!

References

  1. Fabian, I.D.; Onadim, Z.; Karaa, E.; Duncan, C.; Chowdhury, T.; Scheimberg, I.; Ohnuma, S.-I.; Reddy, M.A.; Sagoo, M.S. The management of retinoblastoma. Oncogene 2018, 37, 1551–1560.
  2. Balmer, A.; Munier, F. Differential diagnosis of leukocoria and strabismus, first presenting signs of retinoblastoma. Clin. Ophthalmol. 2007, 1, 431.
  3. Parveen, S.; Sahoo, S.K. Evaluation of cytotoxicity and mechanism of apoptosis of doxorubicin using folate-decorated chitosan nanoparticles for targeted delivery to retinoblastoma. Cancer Nanotechnol. 2010, 1, 47–62.
  4. Balmer, A.; Zografos, L.; Munier, F. Diagnosis and current management of retinoblastoma. Oncogene 2006, 25, 5341–5349.
  5. Lohmann, D.R.; Gerick, M.; Brandt, B.; Oelschläger, U.; Lorenz, B.; Passarge, E.; Horsthemke, B. Constitutional RB1-gene mutations in patients with isolated unilateral retinoblastoma. Am. J. Hum. Genet. 1997, 61, 282–294.
  6. Shields, C.L.; Shields, J.A. Diagnosis and management of retinoblastoma. Cancer Control 2004, 11, 317–327.
  7. Jockovich, M.-E.; Bajenaru, M.L.; Pina, Y.; Suarez, F.; Feuer, W.; Fini, M.E.; Murray, T.G. Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LHBETATAG mouse model. Investig. Ophthalmol. Vis. Sci. 2007, 48, 2476–2482.
  8. Shields, C.L.; Shields, J.A.; De Potter, P.; Minelli, S.; Hernandez, C.; Brady, L.W.; Cater, J.R. Plaque radiotherapy in the management of retinoblastoma: Use as a primary and secondary treatment. Ophthalmology 1993, 100, 216–224.
  9. Murphree, A.L.; Villablanca, J.G.; Deegan, W.F.; Sato, J.K.; Malogolowkin, M.; Fisher, A.; Parker, R.; Reed, E.; Gomer, C.J. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch. Ophthalmol. 1996, 114, 1348–1356.
  10. Chan, H.; Gallie, B.L.; Munier, F.L.; Beck, M.P. Chemotherapy for retinoblastoma. Ophthalmol. Clin. North Am. 2005, 18, 55–63, viii.
  11. Deegan, W.F. Emerging strategies for the treatment of retinoblastoma. Curr. Opin. Ophthalmol. 2003, 14, 291–295.
  12. Zhou, H.-Y.; Hao, J.-L.; Wang, S.; Zheng, Y.; Zhang, W.-S. Nanoparticles in the ocular drug delivery. Int. J. Ophthalmol. 2013, 6, 390.
  13. Thrimawithana, T.R.; Young, S.; Bunt, C.R.; Green, C.; Alany, R.G. Drug delivery to the posterior segment of the eye. Drug Discov. Today 2011, 16, 270–277.
  14. Baranei, M.; Taheri, R.A.; Tirgar, M.; Saeidi, A.; Oroojalian, F.; Uzun, L.; Asefnejad, A.; Wurm, F.R.; Goodarzi, V. Anticancer effect of green tea extract (GTE)-Loaded pH-responsive niosome Coated with PEG against different cell lines. Mater. Today Commun. 2020, 26, 101751.
  15. Barani, M.; Bilal, M.; Rahdar, A.; Arshad, R.; Kumar, A.; Hamishekar, H.; Kyzas, G.Z. Nanodiagnosis and nanotreatment of colorectal cancer: An overview. J. Nanoparticle Res. 2021, 23, 1–25.
  16. Barani, M.; Bilal, M.; Sabir, F.; Rahdar, A.; Kyzas, G.Z. Nanotechnology in ovarian cancer: Diagnosis and treatment. Life Sci. 2020, 266, 118914.
  17. Barani, M.; Mirzaei, M.; Mahani, M.T.; Nematollahi, M.H. Lawsone-loaded Niosome and its Antitumor Activity in MCF-7 Breast Cancer Cell Line: A Nano-herbal Treatment for Cancer. DARU J. Pharm. Sci. 2018, 1–7.
  18. Barani, M.; Mirzaei, M.; Torkzadeh-Mahani, M.; Adeli-Sardou, M. Evaluation of carum-loaded niosomes on breast cancer cells: Physicochemical properties, in vitro cytotoxicity, flow cytometric, DNA fragmentation and cell migration assay. Sci. Rep. 2019, 9, 1–10.
  19. Murray, T.G.; Cicciarelli, N.; O’Brien, J.M.; Hernandez, E.; Mueller, R.L.; Smith, B.J.; Feuer, W. Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma. Arch. Ophthalmol. 1997, 115, 1286–1290.
  20. Kang, S.J.; Durairaj, C.; Kompella, U.B.; O’Brien, J.M.; Grossniklaus, H.E. Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Arch. Ophthalmol. 2009, 127, 1043–1047.
  21. Van Quill, K.R.; Dioguardi, P.K.; Tong, C.T.; Gilbert, J.A.; Aaberg, T.M., Jr.; Grossniklaus, H.E.; Edelhauser, H.F.; O’Brien, J.M. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology 2005, 112, 1151–1158.
  22. Chen, F.; Si, P.; de la Zerda, A.; Jokerst, J.V.; Myung, D. Gold nanoparticles to enhance ophthalmic imaging. Biomater. Sci. 2021, 9, 367–390.
  23. Eide, N.; Walaas, L. Fine-needle aspiration biopsy and other biopsies in suspected intraocular malignant disease: A review. Acta Ophthalmol. 2009, 87, 588–601.
  24. Barani, M.; Mirzaei, M.; Torkzadeh-Mahani, M.; Lohrasbi-Nejad, A.; Nematollahi, M.H. A new formulation of hydrophobin-coated niosome as a drug carrier to cancer cells. Mater. Sci. Eng. C 2020, 113, 110975.
  25. Barani, M.; Mukhtar, M.; Rahdar, A.; Sargazi, G.; Thysiadou, A.; Kyzas, G.Z. Progress in the Application of Nanoparticles and Graphene as Drug Carriers and on the Diagnosis of Brain Infections. Molecules 2021, 26, 186.
  26. Barani, M.; Nematollahi, M.H.; Zaboli, M.; Mirzaei, M.; Torkzadeh-Mahani, M.; Pardakhty, A.; Karam, G.A. In silico and in vitro study of magnetic niosomes for gene delivery: The effect of ergosterol and cholesterol. Mater. Sci. Eng. C 2019, 94, 234–246.
  27. Barani, M.; Sabir, F.; Rahdar, A.; Arshad, R.; Kyzas, G.Z. Nanotreatment and Nanodiagnosis of Prostate Cancer: Recent Updates. Nanomaterials 2020, 10, 1696.
  28. Barani, M.; Torkzadeh-Mahani, M.; Mirzaei, M.; Nematollahi, M.H. Comprehensive evaluation of gene expression in negative and positive trigger-based targeting niosomes in HEK-293 cell line. Iran. J. Pharm. Res. IJPR 2020, 19, 166.
  29. Bilal, M.; Barani, M.; Sabir, F.; Rahdar, A.; Kyzas, G.Z. Nanomaterials for the treatment and diagnosis of Alzheimer’s disease: An overview. NanoImpact 2020, 100251.
  30. Das, S.S.; Bharadwaj, P.; Bilal, M.; Barani, M.; Rahdar, A.; Taboada, P.; Bungau, S.; Kyzas, G.Z. Stimuli-responsive polymeric nanocarriers for drug delivery, imaging, and theragnosis. Polymers 2020, 12, 1397.
  31. Davarpanah, F.; Yazdi, A.K.; Barani, M.; Mirzaei, M.; Torkzadeh-Mahani, M. Magnetic delivery of antitumor carboplatin by using PEGylated-Niosomes. DARU J. Pharm. Sci. 2018, 26, 57–64.
  32. Ebrahimi, A.K.; Barani, M.; Sheikhshoaie, I. Fabrication of a new superparamagnetic metal-organic framework with core-shell nanocomposite structures: Characterization, biocompatibility, and drug release study. Mater. Sci. Eng. C 2018, 92, 349–355.
  33. Ghazy, E.; Kumar, A.; Barani, M.; Kaur, I.; Rahdar, A.; Behl, T. Scrutinizing the Therapeutic and Diagnostic Potential of Nanotechnology in Thyroid Cancer: Edifying drug targeting by nano-oncotherapeutics. J. Drug Deliv. Sci. Technol. 2020, 102221.
  34. Ghazy, E.; Rahdar, A.; Barani, M.; Kyzas, G.Z. Nanomaterials for Parkinson disease: Recent progress. J. Mol. Struct. 2020, 129698.
  35. Hajizadeh, M.R.; Maleki, H.; Barani, M.; Fahmidehkar, M.A.; Mahmoodi, M.; Torkzadeh-Mahani, M. In vitro cytotoxicity assay of D-limonene niosomes: An efficient nano-carrier for enhancing solubility of plant-extracted agents. Res. Pharm. Sci. 2019, 14, 448.
  36. Hajizadeh, M.R.; Parvaz, N.; Barani, M.; Khoshdel, A.; Fahmidehkar, M.A.; Mahmoodi, M.; Torkzadeh-Mahani, M. Diosgenin-loaded niosome as an effective phytochemical nanocarrier: Physicochemical characterization, loading efficiency, and cytotoxicity assay. DARU J. Pharm. Sci. 2019, 27, 329–339.
  37. Zahin, N.; Anwar, R.; Tewari, D.; Kabir, M.T.; Sajid, A.; Mathew, B.; Uddin, M.S.; Aleya, L.; Abdel-Daim, M.M. Nanoparticles and its biomedical applications in health and diseases: Special focus on drug delivery. Environ. Sci. Pollut. Res. 2019, 1–18.
  38. Si, X.-Y.; Merlin, D.; Xiao, B. Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease. World J. Gastroenterol. 2016, 22, 7718.
  39. Weng, Y.; Liu, J.; Jin, S.; Guo, W.; Liang, X.; Hu, Z. Nanotechnology-based strategies for treatment of ocular disease. Acta Pharm. Sin. B 2017, 7, 281–291.
  40. Kompella, U.B.; Amrite, A.C.; Ravi, R.P.; Durazo, S.A. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog. Retinal Eye Res. 2013, 36, 172–198.
  41. Ruchit, T.; Tyagi, P.; Vooturi, S.; Kompella, U. Deslorelin and transferrin mono-and dual-functionalized nanomicelles for drug delivery to the anterior segment of the eye. Investig. Ophthalmol. Vis. Sci. 2013, 54, 3203.
  42. Sahay, G.; Alakhova, D.Y.; Kabanov, A.V. Endocytosis of nanomedicines. J. Control. Release 2010, 145, 182–195.
  43. Scheinman, R.I.; Trivedi, R.; Vermillion, S.; Kompella, U.B. Functionalized STAT1 siRNA nanoparticles regress rheumatoid arthritis in a mouse model. Nanomedicine 2011, 6, 1669–1682.
  44. Kleinman, M.E.; Yamada, K.; Takeda, A.; Chandrasekaran, V.; Nozaki, M.; Baffi, J.Z.; Albuquerque, R.J.; Yamasaki, S.; Itaya, M.; Pan, Y. Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008, 452, 591–597.
  45. Sundaram, S.; Roy, S.K.; Ambati, B.K.; Kompella, U.B. Surface-functionalized nanoparticles for targeted gene delivery across nasal respiratory epithelium. FASEB J. 2009, 23, 3752–3765.
  46. Conley, S.M.; Naash, M.I. Nanoparticles for retinal gene therapy. Prog. Retin. Eye Res. 2010, 29, 376–397.
  47. Mitra, M.; Misra, R.; Harilal, A.; Sahoo, S.K.; Krishnakumar, S. Enhanced in vitro antiproliferative effects of EpCAM antibody-functionalized paclitaxel-loaded PLGA nanoparticles in retinoblastoma cells. Mol. Vis. 2011, 17, 2724.
  48. Hasanein, P.; Rahdar, A.; Barani, M.; Baino, F.; Yari, S. Oil-In-Water Microemulsion Encapsulation of Antagonist Drugs Prevents Renal Ischemia-Reperfusion Injury in Rats. Appl. Sci. 2021, 11, 1264.
  49. Mukhtar, M.; Bilal, M.; Rahdar, A.; Barani, M.; Arshad, R.; Behl, T.; Brisc, C.; Banica, F.; Bungau, S. Nanomaterials for Diagnosis and Treatment of Brain Cancer: Recent Updates. Chemosensors 2020, 8, 117.
  50. Nikazar, S.; Barani, M.; Rahdar, A.; Zoghi, M.; Kyzas, G.Z. Photo-and Magnetothermally Responsive Nanomaterials for Therapy, Controlled Drug Delivery and Imaging Applications. ChemistrySelect 2020, 5, 12590–12609.
  51. Rahdar, A.; Hajinezhad, M.R.; Nasri, S.; Beyzaei, H.; Barani, M.; Trant, J.F. The synthesis of methotrexate-loaded F127 microemulsions and their in vivo toxicity in a rat model. J. Mol. Liquids 2020, 313, 113449.
  52. Rahdar, A.; Hajinezhad, M.R.; Sargazi, S.; Barani, M.; Bilal, M.; Kyzas, G.Z. Deferasirox-loaded pluronic nanomicelles: Synthesis, characterization, in vitro and in vivo studies. J. Mol. Liquids 2021, 323, 114605.
  53. Rahdar, A.; Hajinezhad, M.R.; Sargazi, S.; Bilal, M.; Barani, M.; Karimi, P.; Kyzas, G.Z. Biochemical effects of deferasirox and deferasirox-loaded nanomicellesin iron-intoxicated rats. Life Sci. 2021, 119146.
  54. Rahdar, A.; Taboada, P.; Hajinezhad, M.R.; Barani, M.; Beyzaei, H. Effect of tocopherol on the properties of Pluronic F127 microemulsions: Physico-chemical characterization and in vivo toxicity. J. Mol. Liquids 2019, 277, 624–630.
  55. Barani, M.; Mukhtar, M.; Rahdar, A.; Sargazi, S.; Pandey, S.; Kang, M. Recent Advances in Nanotechnology-Based Diagnosis and Treatments of Human Osteosarcoma. Biosensors 2021, 11, 55.
  56. Torkzadeh-Mahani, M.; Zaboli, M.; Barani, M.; Torkzadeh-Mahani, M. A combined theoretical and experimental study to improve the thermal stability of recombinant D-lactate dehydrogenase immobilized on a novel superparamagnetic Fe3O4 metal–organic framework. Appl. Organomet. Chem. 2020, 34, e5581.
  57. Cordray, M.S.; Amdahl, M.; Richards-Kortum, R.R. Gold nanoparticle aggregation for quantification of oligonucleotides: Optimization and increased dynamic range. Anal. Biochem. 2012, 431, 99–105.
  58. Donaldson, K.; Schinwald, A.; Murphy, F.; Cho, W.-S.; Duffin, R.; Tran, L.; Poland, C. The biologically effective dose in inhalation nanotoxicology. Acc. Chem. Res. 2013, 46, 723–732.
  59. Kimura, K.; Usui, Y.; Goto, H. Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. Jpn. J. Ophthalmol. 2012, 56, 383–389.
  60. Weiss, L. Analysis of the incidence of intraocular metastasis. Br. J. Ophthalmol. 1993, 77, 149–151.
  61. Dimaras, H.; Kimani, K.; Dimba, E.A.; Gronsdahl, P.; White, A.; Chan, H.S.; Gallie, B.L. Retinoblastoma. Lancet 2012, 379, 1436–1446.
  62. Rao, R.; Honavar, S.G. Retinoblastoma. Indian J. Pediatrics 2017, 84, 937–944.
  63. Mattosinho, C.C.D.S.; Moura, A.T.M.; Oigman, G.; Ferman, S.E.; Grigorovski, N. Time to diagnosis of retinoblastoma in Latin America: A systematic review. Pediatric Hematol. Oncol. 2019, 36, 55–72.
  64. Giacalone, M.; Mastrangelo, G.; Parri, N. Point-of-care ultrasound diagnosis of retinoblastoma in the emergency department. Pediatric Emerg. Care 2018, 34, 599–601.
  65. Khoo, S.A.; Ong, G.Y.-K. Use of Ocular Point-of-Care Ultrasound in a Difficult Pediatric Examination: A Case Report of an Emergency Department Diagnosis of Retinoblastoma. J. Emerg. Med. 2020, 58, 632–635.
  66. Li, Z.; Guo, J.; Xu, X.; Wang, Y.; Mukherji, S.K.; Xian, J. Diagnosis of Postlaminar optic nerve invasion in retinoblastoma with MRI features. J. Magn. Reson. Imaging 2020, 51, 1045–1052.
  67. Neupane, R.; Gaudana, R.; Boddu, S.H. Imaging techniques in the diagnosis and management of ocular tumors: Prospects and challenges. AAPS J. 2018, 20, 1–12.
  68. Sun, J.; Xi, H.-Y.; Shao, Q.; Liu, Q.-H. Biomarkers in retinoblastoma. Int. J. Ophthalmol. 2020, 13, 325.
  69. Golabchi, K.; Soleimani-Jelodar, R.; Aghadoost, N.; Momeni, F.; Moridikia, A.; Nahand, J.S.; Masoudifar, A.; Razmjoo, H.; Mirzaei, H. MicroRNAs in retinoblastoma: Potential diagnostic and therapeutic biomarkers. J. Cell. Physiol. 2018, 233, 3016–3023.
  70. Chen, X.-J.; Zhang, X.-Q.; Liu, Q.; Zhang, J.; Zhou, G. Nanotechnology: A promising method for oral cancer detection and diagnosis. J. Nanobiotechnol. 2018, 16, 1–17.
  71. Sabir, F.; Barani, M.; Rahdar, A.; Bilal, M.; Zafar, N.M.; Bungau, S.; Kyzas, G.Z. How to Face Skin Cancer with Nanomaterials: A Review. Biointerface Res. Appl. Chem. 2021, 11, 11931–11955.
  72. Zhang, Y.; Li, M.; Gao, X.; Chen, Y.; Liu, T. Nanotechnology in cancer diagnosis: Progress, challenges and opportunities. J. Hematol. Oncol. 2019, 12, 1–13.
  73. Kim, H.; Van Phuc Nguyen, P.M.; Jung, M.J.; Kim, S.W.; Oh, J.; Kang, H.W. Doxorubicin-fucoidan-gold nanoparticles composite for dual-chemo-photothermal treatment on eye tumors. Oncotarget 2017, 8, 113719.
  74. Cruz-Alonso, M.; Fernandez, B.; Álvarez, L.; González-Iglesias, H.; Traub, H.; Jakubowski, N.; Pereiro, R. Bioimaging of metallothioneins in ocular tissue sections by laser ablation-ICP-MS using bioconjugated gold nanoclusters as specific tags. Microchim. Acta 2018, 185, 1–9.
  75. Lapierre-Landry, M.; Gordon, A.Y.; Penn, J.S.; Skala, M.C. In vivo photothermal optical coherence tomography of endogenous and exogenous contrast agents in the eye. Sci. Rep. 2017, 7, 1–9.
  76. Jaidev, L.; Chellappan, D.R.; Bhavsar, D.V.; Ranganathan, R.; Sivanantham, B.; Subramanian, A.; Sharma, U.; Jagannathan, N.R.; Krishnan, U.M.; Sethuraman, S. Multi-functional nanoparticles as theranostic agents for the treatment & imaging of pancreatic cancer. Acta Biomater. 2017, 49, 422–433.
  77. Toda, M.; Yukawa, H.; Yamada, J.; Ueno, M.; Kinoshita, S.; Baba, Y.; Hamuro, J. In vivo fluorescence visualization of anterior chamber injected human corneal endothelial cells labeled with quantum dots. Investig. Ophthalmol. Vis. Sci. 2019, 60, 4008–4020.
  78. Goto, K.; Kato, D.; Sekioka, N.; Ueda, A.; Hirono, S.; Niwa, O. Direct electrochemical detection of DNA methylation for retinoblastoma and CpG fragments using a nanocarbon film. Anal. Biochem. 2010, 405, 59–66.
  79. Wang, M.; Yang, Q.; Li, M.; Zou, H.; Wang, Z.; Ran, H.; Zheng, Y.; Jian, J.; Zhou, Y.; Luo, Y.; et al. Multifunctional Nanoparticles for Multimodal Imaging-Guided Low-Intensity Focused Ultrasound/Immunosynergistic Retinoblastoma Therapy. ACS Appl. Mater. Interfaces 2020, 12, 5642–5657.
  80. Garner, I.; Vichare, R.; Paulson, R.; Appavu, R.; Panguluri, S.K.; Tzekov, R.; Sahiner, N.; Ayyala, R.; Biswal, M.R. Carbon dots fabrication: Ocular imaging and therapeutic potential. Front. Bioeng. Biotechnol. 2020, 8, 1139.
  81. Sarwat, S.; Stapleton, F.; Willcox, M.; Roy, M. Quantum Dots in Ophthalmology: A Literature Review. Curr. Eye Res. 2019, 44, 1037–1046.
  82. Mahan, M.M.; Doiron, A.L. Gold nanoparticles as X-ray, CT, and multimodal imaging contrast agents: Formulation, targeting, and methodology. J. Nanomater. 2018, 2018.
  83. Altundal, Y.; Sajo, E.; Makrigiorgos, G.M.; Berbeco, R.I.; Ngwa, W. Nanoparticle-aided radiotherapy for retinoblastoma and choroidal melanoma. In Proceedings of the World Congress on Medical Physics and Biomedical Engineering, Toronto, ON, Canada, 7–12 June 2015; pp. 907–910.
  84. Moradi, S.; Mokhtari-Dizaji, M.; Ghassemi, F.; Sheibani, S.; Asadi Amoli, F. Increasing the efficiency of the retinoblastoma brachytherapy protocol with ultrasonic hyperthermia and gold nanoparticles: A rabbit model. Int. J. Radiat. Biol. 2020, 96, 1614–1627.
  85. Mohajeri, M.; Behnam, B.; Sahebkar, A. Biomedical applications of carbon nanomaterials: Drug and gene delivery potentials. J. Cell. Physiol. 2019, 234, 298–319.
  86. Power, A.C.; Gorey, B.; Chandra, S.; Chapman, J. Carbon nanomaterials and their application to electrochemical sensors: A review. Nanotechnol. Rev. 2018, 7, 19–41.
  87. Farzin, A.; Etesami, S.A.; Quint, J.; Memic, A.; Tamayol, A. Magnetic nanoparticles in cancer therapy and diagnosis. Adv. Healthc. Mater. 2020, 9, 1901058.
  88. Tzameret, A.; Ketter-Katz, H.; Edelshtain, V.; Sher, I.; Corem-Salkmon, E.; Levy, I.; Last, D.; Guez, D.; Mardor, Y.; Margel, S. In vivo MRI assessment of bioactive magnetic iron oxide/human serum albumin nanoparticle delivery into the posterior segment of the eye in a rat model of retinal degeneration. J. Nanobiotechnol. 2019, 17, 1–11.
  89. Dimaras, H.; Corson, T.W.; Cobrinik, D.; White, A.; Zhao, J.; Munier, F.L.; Abramson, D.H.; Shields, C.L.; Chantada, G.L.; Njuguna, F. Retinoblastoma. Nat. Rev. Dis. Primers 2015, 1, 1–23.
  90. Jain, M.; Rojanaporn, D.; Chawla, B.; Sundar, G.; Gopal, L.; Khetan, V. Retinoblastoma in Asia. Eye 2019, 33, 87–96.
  91. Mehyar, M.; Mosallam, M.; Tbakhi, A.; Saab, A.; Sultan, I.; Deebajah, R.; Jaradat, I.; AlJabari, R.; Mohammad, M.; AlNawaiseh, I. Impact of RB1 gene mutation type in retinoblastoma patients on clinical presentation and management outcome. Hematol. Oncol. Stem Cell Ther. 2020, 13, 152–159.
  92. Cocarta, A.-I.; Hobzova, R.; Sirc, J.; Cerna, T.; Hrabeta, J.; Svojgr, K.; Pochop, P.; Kodetova, M.; Jedelska, J.; Bakowsky, U. Hydrogel implants for transscleral drug delivery for retinoblastoma treatment. Mater. Sci. Eng. C 2019, 103, 109799.
  93. Xue, K.; Ren, H.; Meng, F.; Zhang, R.; Qian, J. Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients. BMC Ophthalmol. 2019, 19, 1–8.
  94. Kleinerman, R.A.; Tucker, M.A.; Sigel, B.S.; Abramson, D.H.; Seddon, J.M.; Morton, L.M. Patterns of cause-specific mortality among 2053 survivors of retinoblastoma, 1914–2016. JNCI J. Natl. Cancer Inst. 2019, 111, 961–969.
  95. Dimaras, H.; Corson, T.W. Retinoblastoma, the visible CNS tumor: A review. J. Neurosci. Res. 2019, 97, 29–44.
  96. Raguraman, R.; Parameswaran, S.; Kanwar, J.R.; Khetan, V.; Rishi, P.; Kanwar, R.K.; Krishnakumar, S. Evidence of tumour microenvironment and stromal cellular components in retinoblastoma. Ocular Oncol. Pathol. 2019, 5, 85–93.
  97. Pérez-Herrero, E.; Fernández-Medarde, A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur. J. Pharm. Biopharm. 2015, 93, 52–79.
  98. Jabr-Milane, L.S.; van Vlerken, L.E.; Yadav, S.; Amiji, M.M. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev. 2008, 34, 592–602.
  99. Mendoza, P.R.; Grossniklaus, H.E. Therapeutic options for retinoblastoma. Cancer Control 2016, 23, 99–109.
  100. Bhavsar, D.; Subramanian, K.; Sethuraman, S.; Krishnan, U.M. Management of retinoblastoma: Opportunities and challenges. Drug Deliv. 2016, 23, 2488–2496.
  101. Gao, R.; Mitra, R.N.; Zheng, M.; Wang, K.; Dahringer, J.C.; Han, Z. Developing Nanoceria-Based pH-Dependent Cancer-Directed Drug Delivery System for Retinoblastoma. Adv. Funct. Mater. 2018, 28, 1806248.
  102. Sims, L.B.; Tyo, K.M.; Stocke, S.; Mahmoud, M.Y.; Ramasubramanian, A.; Steinbach-Rankins, J.M. Surface-Modified Melphalan Nanoparticles for Intravitreal Chemotherapy of Retinoblastoma. Investig. Ophthalmol. Vis. Sci. 2019, 60, 1696–1705.
  103. Godse, R.; Rathod, M.; De, A.; Shinde, U. Intravitreal galactose conjugated polymeric nanoparticles of etoposide for retinoblastoma. J. Drug Deliv. Sci. Technol. 2021, 61, 102259.
  104. Martens, T.F.; Peynshaert, K.; Nascimento, T.L.; Fattal, E.; Karlstetter, M.; Langmann, T.; Picaud, S.; Demeester, J.; De Smedt, S.C.; Remaut, K. Effect of hyaluronic acid-binding to lipoplexes on intravitreal drug delivery for retinal gene therapy. Eur. J. Pharm. Sci. 2017, 103, 27–35.
  105. Correia, A.R.; Sampaio, I.; Comparetti, E.J.; Vieira, N.C.S.; Zucolotto, V. Optimized PAH/Folic acid layer-by-layer films as an electrochemical biosensor for the detection of folate receptors. Bioelectrochemistry 2020, 137, 107685.
  106. Tabatabaei, S.N.; Derbali, R.M.; Yang, C.; Superstein, R.; Hamel, P.; Chain, J.L.; Hardy, P. Co-delivery of miR-181a and melphalan by lipid nanoparticles for treatment of seeded retinoblastoma. J. Control. Release 2019, 298, 177–185.
  107. Chugh, H.; Sood, D.; Chandra, I.; Tomar, V.; Dhawan, G.; Chandra, R. Role of gold and silver nanoparticles in cancer nano-medicine. Artif. Cells Nanomed. Biotechnol. 2018, 46, 1210–1220.
  108. Chen, Y.; Sun, S.; Li, C.; Hao, Y. Rosiglitazone Gold Nanoparticles Attenuate the Development of Retinoblastoma by Repressing the PI3K/Akt Pathway. Nanosci. Nanotechnol. Lett. 2020, 12, 820–826.
  109. Guo, X.; Zhuang, Q.; Ji, T.; Zhang, Y.; Li, C.; Wang, Y.; Li, H.; Jia, H.; Liu, Y.; Du, L. Multi-functionalized chitosan nanoparticles for enhanced chemotherapy in lung cancer. Carbohydr. Polym. 2018, 195, 311–320.
  110. Song, Y.; Tang, C.; Yin, C. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells. Biomaterials 2018, 185, 117–132.
  111. Martens, T.F.; Remaut, K.; Deschout, H.; Engbersen, J.F.; Hennink, W.E.; Van Steenbergen, M.J.; Demeester, J.; De Smedt, S.C.; Braeckmans, K. Coating nanocarriers with hyaluronic acid facilitates intravitreal drug delivery for retinal gene therapy. J. Control. Release 2015, 202, 83–92.
  112. Keating, J.J.; Runge, J.J.; Singhal, S.; Nims, S.; Venegas, O.; Durham, A.C.; Swain, G.; Nie, S.; Low, P.S.; Holt, D.E. Intraoperative near-infrared fluorescence imaging targeting folate receptors identifies lung cancer in a large-animal model. Cancer 2017, 123, 1051–1060.
  113. Chen, C.; Ke, J.; Zhou, X.E.; Yi, W.; Brunzelle, J.S.; Li, J.; Yong, E.-L.; Xu, H.E.; Melcher, K. Structural basis for molecular recognition of folic acid by folate receptors. Nature 2013, 500, 486–489.
  114. De Moraes Profirio, D.; Pessine, F.B.T. Formulation of functionalized PLGA nanoparticles with folic acid-conjugated chitosan for carboplatin encapsulation. Eur. Polym. J. 2018, 108, 311–321.
  115. Ramishetti, S.; Hazan-Halevy, I.; Palakuri, R.; Chatterjee, S.; Naidu Gonna, S.; Dammes, N.; Freilich, I.; Kolik Shmuel, L.; Danino, D.; Peer, D. A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes. Adv. Mater. 2020, 32, 1906128.
  116. Patel, S.; Ashwanikumar, N.; Robinson, E.; Xia, Y.; Mihai, C.; Griffith, J.P.; Hou, S.; Esposito, A.A.; Ketova, T.; Welsher, K. Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA. Nat. Commun. 2020, 11, 1–13.
  117. Yu, X.; Dai, Y.; Zhao, Y.; Qi, S.; Liu, L.; Lu, L.; Luo, Q.; Zhang, Z. Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response. Nat. Commun. 2020, 11, 1–14.
  118. Lingayat, V.J.; Zarekar, N.S.; Shendge, R.S. Solid lipid nanoparticles: A review. Nanosci. Nanotechnol. Res. 2017, 2, 67–72.
  119. Paliwal, R.; Paliwal, S.R.; Kenwat, R.; Kurmi, B.D.; Sahu, M.K. Solid lipid nanoparticles: A review on recent perspectives and patents. Expert Opin. Ther. Pat. 2020, 30, 179–194.
  120. Ban, C.; Jo, M.; Park, Y.H.; Kim, J.H.; Han, J.Y.; Lee, K.W.; Kweon, D.-H.; Choi, Y.J. Enhancing the oral bioavailability of curcumin using solid lipid nanoparticles. Food Chem. 2020, 302, 125328.
  121. Ahmad, I.; Pandit, J.; Sultana, Y.; Mishra, A.K.; Hazari, P.P.; Aqil, M. Optimization by design of etoposide loaded solid lipid nanoparticles for ocular delivery: Characterization, pharmacokinetic and deposition study. Mater. Sci. Eng. C 2019, 100, 959–970.
  122. Crommelin, D.J.; van Hoogevest, P.; Storm, G. The role of liposomes in clinical nanomedicine development. What now? Now what? J. Control. Release 2020, 318, 256–263.
  123. Tai, K.; Rappolt, M.; Mao, L.; Gao, Y.; Li, X.; Yuan, F. The stabilization and release performances of curcumin-loaded liposomes coated by high and low molecular weight chitosan. Food Hydrocoll. 2020, 99, 105355.
  124. Zhao, L.; Wang, F.; Fan, W. Cisplatin Nano-Liposomes Promoting Apoptosis of Retinoblastoma Cells Both In Vivo and In Vitro. Nanosci. Nanotechnol. Lett. 2020, 12, 536–542.
More